ResMed’s Operational Excellence Comes to its Rescue

Team Veye | 06-Aug-2024

ResMed’s operational excellence comes to its rescue in challenging market conditions

ResMed Inc (ASX: RMD)

The company has highlighted its continuing patient and customer demand for its best-in-class products. Along with this, the strong demand for its software solutions is driving solid growth across its devices, masks, and software businesses

ResMed maintains focus on its constant cost discipline, and Profitable Growth Acceleration, which has resulted in gross margin expansion, and double-digit growth in bottom-line profitability.

ResMed Inc while releasing its quarterly financial results for the fourth quarter of FY24 reported witnessing a revenue increase of 10 percent on a constant currency basis, primarily fuelled by heightened demand for its sleep devices and masks, alongside robust growth in its Software as a Service segment.

The gross margin saw an enhancement of 350 basis points, largely attributed to reductions in freight and manufacturing costs, an uptick in average selling prices, and a favourable product mix. The non-GAAP gross margin also rose by 330 basis points, reflecting similar contributing factors.

The net income for the quarter reached $292 million, with diluted earnings per share standing at $1.98. Non-GAAP net income surged by 30 percent to $306 million, while non-GAAP diluted earnings per share increased by 30 percent to $2.08, primarily due to strong sales performance, improved gross margins, and a modest rise in operating expenses.

Additionally, during this quarter, the company distributed $71 million in dividends and repurchased 232,000 shares at a cost of $50 million as part of its ongoing Capital Management Strategy.

The company is observing ongoing positive performance in its operating segments, with a particular emphasis on the continuous growth in demand for its medical devices, masks, and software services. This growth is underpinned by a Strong Market Opportunity, as a substantial portion of the population is affected by sleep and breathing disorders, thereby supporting a resilient sales platform.

The company has demonstrated impressive double-digit revenue growth rates in both the recent quarter and the previous year, displaying a strong track record of financial expansion. Earnings have shown a notable increase from $927 million in 2019 to $1.33 billion in 2023. This growth trajectory is supported by the company's solid market position and resilient market fundamentals, indicating that the current robust growth rates are likely to be sustained. 

Source: Company’s Report

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2024

(+61)

DIVIDEND
INVESTER REPORT

Dividend-Investor-Report

Each week we cover companies offering a good combination of growth & dividends, maintaining a balance between stable 'cash flow' and risker 'raising stars'. Our guidance helps you choose companies with regular dividends and opportunities for lower-risk capital growth.

  • The best High Yield Dividend Stocks picked by our team of analysts every week.
  • Detailed in-depth Analysis with our expert Recommendations Buy, Hold or Sell.
  • Free Daily Analysis Report to keep up with the latest on what's hot and what's not.
  • Gain instant access to a wide range of Dividend Share Reports, exclusive to members only.
Frequency: Every Tuesday